Search Results for: car t

BIO, PhRMA and US Chamber of Commerce express fear of UN High-Level Panel on Access to Medicines in letter to Senator Hatch

Posted on by Thiru

In a sternly worded letter dated 18 February 2016, the Biotechnology Innovation Organization (BIO), the National Association of Manufacturers (NAM), the National Foreign Trade Council (NFTC), the Pharmaceutical Research and Manufacturers of America (PhRMA), the U.S. Chamber of Commerce (the Chamber) and the United States Council for International Business (USCIB) wrote Senator Orrin Hatch (Republican – Utah) expressing serious reservations with the United Nations High-Level Panel on Access to Medicines (UN HLP). Continue Reading →

Briefing on Beijing Treaty on Audiovisual Performers

Posted on by Manon Ress

On Monday, March 7, 2016, from 1:45 P.M. to 2:45 P.M., the US Patent and Trademark Office (USPTO) met with invited stakeholders in a briefing at the White House on the Beijing Treaty on Audiovisual Performances and the implementation package that was sent to Congress on February 29, 2016. The package was submitted for review to the Senate Foreign Relations and Judiciary Committees.

Continue Reading →

Uncategorized

Congressman Doggett Voices Support for KEI/UACT Petition to NIH on Xtandi

Posted on by Zack Struver

On Monday, March 7, 2016, Congressman Lloyd Doggett, D-Texas, issued a statement in support of the recent Knowledge Ecology International (KEI) and Union for Affordable Cancer Treatment (UACT) request that the National Institutes of Health (NIH) authorize the generic production of an expensive prostate cancer drug in order to curb an excessive and discriminatory price in the United States.

Continue Reading →

KEI comments to the Senate Finance Committee Report on the Price of Sovaldi

Posted on by James Love

On March 4, 2016, KEI provided comments to the US Senate Committee on Finance on a report prepared by staff for Senators Grassley and Wyden that was issued by the committee on December 2015, titled “The Price of Sovaldi and Its Impact on the U.S. Health Care System.” Senators Grassley and Wyden asked the public to comment on various issues raised in the report. The comments we filed on March 4 included three major sections.

Continue Reading →

Uncategorized

Colombia takes an important step in defining the public interest in compulsory licensing case

Posted on by James Love

(More on Colombia here: /colombia)

Andrea Carolina Reyes Rojas informs us that a committee appointed to consider a request for a compulsory license on the leukemia drug Imatinib has decided that there are public interest reasons to do so.

A copy of the decision is available here. Andrew Goldman shares some thoughts and context here.

Continue Reading →

Uncategorized

2016: AltraTech, KEI comments on NIH proposal for exclusive licenses for vitro diagnostics patents

Posted on by KEI Staff

Other KEI comments on NIH licenses are found here: /nih-licenses

February 22, 2016

Patrick McCue, Ph.D.
Senior Licensing and Patenting Manager
Technology Advancement Office
The National Institutes of Diabetes and Digestive and Kidney Diseases
12A South Drive
Bethesda, MD 20892
via email: patrick.mccue@nih.gov

Dear Dr. McCue:

Continue Reading →

Uncategorized